The global osteoarthritis therapeutics market should reach $11.2 billion by 2026 from $7.4 billion in 2021 at a compound annual growth rate (CAGR) of 8.6% for the forecast period of 2021 to 2026.
The knee osteoarthritis segment of the global osteoarthritis therapeutics market is expected to grow from $5.9 billion in 2021 to $9.0 billion in 2026 at a CAGR of 8.8% for the forecast period of 2021 to 2026.
The hip osteoarthritis segment of the global osteoarthritis therapeutics market is expected to grow from $939.1 million in 2021 to $1.4 billion in 2026 at a CAGR of 8.4% for the forecast period of 2021 to 2026.
This report provides a detailed description of the approaches used to treat pain management associated with osteoarthritis and the latest updates in the market.
The Report Includes
- 27 data tables and 33 additional tables
- An overview of the global market for osteoarthritis therapeutics
- Estimation of the market size and analyses of global market trends, with data from 2019 to 2020, estimates for 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the market potential for osteoarthritis therapeutics, based on type of anatomy, drug type, route of administration, purchasing pattern and region
- Discussion on recent developments of agents for the treatment of OA, which includes potential disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics for pain relief
- Description of pharmacological and non-pharmacological methods of OA management and information on personalized medicines for OA
- Discussion on the risk of adverse cardiovascular events related to the use of NSAIDs in osteoarthritis
- Coverage of clinical trials and applications of attractive drugs in preclinical research; regulatory scenarios, ongoing research on anti-NGF therapy and government expenditures
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast, and assessment of new developments in the industry
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players, including Abbott Laboratories Inc., Bayer AG, Eli Lilly and Co., GlaxoSmithKline PLC, Pfizer Inc. and Sanofi.
Report Scope:
- Based on anatomy, the osteoarthritis therapeutics market is segmented into knee osteoarthritis, hip osteoarthritis, others (shoulder, hand and small joint osteoarthritis).
- Based on drug type, the osteoarthritis therapeutics market is segmented as viscosupplementation agents; Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including ibuprofen, aspirin, diclofenac, naproxen, and other NSAIDs; analgesics; and corticosteroids.
- Based on route of administration, the osteoarthritis therapeutics market is segmented into a parenteral route, oral route and topical route.
- Based on drug classification, the osteoarthritis therapeutics market is segmented into prescription drugs and over-the-counter (OTC) drugs.
The report discusses the qualitative and quantitative factors influencing the market growth. Market drivers, restraints and opportunities are discussed in the report.
This report discusses some of the major drivers and restraints in the global osteoarthritis therapeutics market, as well as the competition and the key players’ strategies and performances. The discussion is focused on the major market players, trends in product launches, collaborations, and mergers and acquisitions. The report also includes company profiles of major vendors including company overview, key product offerings, financial statistics and recent developments. The report provides insights on market shares and upcoming regional demand for osteoarthritis therapeutics.
Some of the major market players discussed in the report are Sanofi S.A., Fidia Farmaceutici S.p.A, Seikagaku Corp., Anika Therapeutics Inc., Pfizer Inc. and GlaxoSmithKline PLC. For market estimates, data has been provided for 2020, which serves as the base year, with forecasts for 2021 through 2026. Estimated values used are based on manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.
Table of Contents
Chapter 1 Introduction
- Study Background
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Osteoarthritis
- Etiology
- Epidemiology and Market Burden
- Prevalence of Osteoarthritis
- Disease Symptoms
- Risk Factors
- Diagnosis
- Treatment
- NSAIDs for Pain Management in OA
- Reducing the Risk of Osteoarthritis
Chapter 4 Impact of COVID-19
- Overview
- Osteoarthritis and COVID-19
- Predisposing Comorbidities in OA Patients
- OA Drugs and Viral Infections
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Conclusion
- Direct Impact of COVID-19 on Revenue of Companies
Chapter 5 Market Dynamics
- Market Drivers
- Increasing Prevalence of Knee Osteoarthritis
- Increasing Population (Especially Elderly) Prone to Osteoarthritis, and an Increasing Number of Sports Injuries
- Significant Adoption of Pain Medications
- Market Restraints
- The Risk of Adverse Cardiovascular Events Related to the Use of NSAIDs in Osteoarthritis
- Substitute Treatment Options
- Insurance Denials
- Government Regulations
- Market Opportunities
- Personalized Medicines For OA
- Ongoing Research on Anti-(NGF) Nerve Growth Factor Therapy
- Patient Preference
- Strategic Initiatives
- Competitive Landscape
Chapter 6 Market Breakdown by Anatomy
- Global Market for Osteoarthritis Therapeutics by Anatomy
- Knee Osteoarthritis
- Hip Osteoarthritis
- Others
Chapter 7 Market Breakdown by Drug Type
- Global Market for Osteoarthritis Therapeutics by Drug Type
- Viscosupplementation Agents
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Analgesics
- Corticosteroids
Chapter 8 Market Breakdown by Route of Administration
- Global Market for Osteoarthritis Therapeutics by Route of Administration
- Parenteral Route
- Oral Route
- Topical Route
Chapter 9 Market Breakdown by Drug Classification (OTC/Prescription)
- Global Market for Osteoarthritis Therapeutics by Drug Classification
- Prescription Drugs
- OTC
Chapter 10 Market Breakdown by Region
- Global Market for Osteoarthritis Therapeutics Market by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 11 Company Profiles
- Abbott Laboratories
- Anika Therapeutics Inc.
- Bayer Ag
- Bioventus
- Eli Lilly And Co.
- Ferring B.V.
- Fidia Farmaceutici S.P.A.
- Flexion Therapeutics Inc.
- GlaxoSmithKline Plc
- Horizon Therapeutics Plc
- Johnson & Johnson Inc.
- Novartis Ag
- Pfizer Inc.
- Sanofi
- Seikagaku Corp.
Chapter 12 Appendix: List of Acronyms
List of Tables
Summary Table: Global Market for Osteoarthritis Therapeutics, by Anatomy, Through 2026
Table 1: Classification of Common NSAIDs
Table 2: Potential Role of OA drugs in COVID-19 Pandemic and Other Major Related Events
Table 3: Global Market Ranking of Viscosupplementation Vendors, 2020
Table 4: Global Market Ranking of OA Therapeutics Vendors, 2020
Table 5: Global Market for Osteoarthritis Therapeutics, by Anatomy, Through 2026
Table 6: Treatment Guidelines for Knee OA
Table 7: Global Market for Knee Osteoarthritis Therapeutics, by Region, Through 2026
Table 8: Global Market for Hip Osteoarthritis Therapeutics, by Region, Through 2026
Table 9: Global Market for Other Types of Osteoarthritis Therapeutics (Shoulder, Hand, Small Joint), by Region, Through 2026
Table 10: Global Market for Osteoarthritis Therapeutics, by Drug Type, Through 2026
Table 11: Technical Characteristics of HA (Hyaluronic Acid) injection According to Joint
Table 12: Global Market for Viscosupplementation Agents as Osteoarthritis Therapeutics, by Region, Through 2026
Table 13: Global Market for NSAIDs as Osteoarthritis Therapeutics, by Region, Through 2026
Table 14: Global Market for NSAIDs as Osteoarthritis Therapeutics, by Drug Type, Through 2026
Table 15: Global Market for Analgesics as Osteoarthritis Therapeutics, by Region, Through 2026
Table 16: Global Market for Corticosteroids as Osteoarthritis Therapeutics, by Region, Through 2026
Table 17: Global Market for Osteoarthritis Therapeutics, by Route of Administration, Through 2026
Table 18: Global Market for Osteoarthritis Therapeutics via the Parenteral Route, by Region, Through 2026
Table 19: Global Market for Osteoarthritis Therapeutics via the Oral Route, by Region, Through 2026
Table 20: Global Market for Osteoarthritis Therapeutics via the Topical Route, by Region, Through 2026
Table 21: Global Market for Osteoarthritis Therapeutics, by Drug Classification, Through 2026
Table 22: Global Market for Prescription Osteoarthritis Therapeutics, by Region, Through 2026
Table 23: Global Market for OTC Osteoarthritis Therapeutics, by Region, Through 2026
Table 24: Global Market for Osteoarthritis Therapeutics, by Region, Through 2026
Table 25: North American Market for Osteoarthritis Therapeutics, by Anatomy, Through 2026
Table 26: North American Market for Osteoarthritis Therapeutics, by Country, Through 2026
Table 27: European Market for Osteoarthritis Therapeutics, by Anatomy, Through 2026
Table 28: European Market for Osteoarthritis Therapeutics, by Country, Through 2026
Table 29: Asia-Pacific Market for Osteoarthritis Therapeutics, by Anatomy, Through 2026
Table 30: Asia-Pacific Market for Osteoarthritis Therapeutics, by Country, Through 2026
Table 31: Rest of the World Market for Osteoarthritis Therapeutics, by Anatomy, Through 2026
Table 32: Abbott Laboratories: Products Offered
Table 33: Anika Therapeutics Inc.: Products Offered
Table 34: Anika Therapeutics Inc.: Recent Developments
Table 35: Bayer AG: Products Offered
Table 36: Bioventus: Products Offered
Table 37: Bioventus: Recent Developments
Table 38: Eli Lilly and Co.: Recent Developments
Table 39: Ferring B.V.: Financials, 2019 and 2020
Table 40: Ferring B.V.: Products Offered
Table 41: Fidia Farmaceutici S.p.A.: Products Offered
Table 42: Flexion Therapeutics Inc.: Products/Services Offered
Table 43: Flexion Therapeutics Inc.: Recent Developments
Table 44: GlaxoSmithKline PLC: Products Offered
Table 45: GlaxoSmithKline PLC: Recent Developments
Table 46: Horizon Therapeutics PLC: Product Portfolio Sales, 2020
Table 47: Horizon Therapeutics PLC: Products Offered
Table 48: Horizon Therapeutics PLC: Recent Developments
Table 49: Johnson & Johnson Inc.: Products Offered
Table 50: Johnson & Johnson Inc.: Recent Developments
Table 51: Novartis AG: Products Offered
Table 52: Novartis AG: Recent Developments
Table 53: Pfizer Inc.: Products Offered
Table 54: Pfizer Inc.: Recent Developments 2021
Table 55: Sanofi: Products/Services Offered
Table 56: Sanofi: Recent Developments
Table 57: Seikagaku Corp.: Products/Services Offered
Table 58: Seikagaku Corp.: Recent Developments
Table 59: Acronyms Used in This Report
List of Figures
Summary Figure: Global Market Shares of Osteoarthritis Therapeutics, by Anatomy, 2020
Figure 1: Global Market Shares of Osteoarthritis Therapeutics, by Anatomy, 2020
Figure 2: Global Market for Knee Osteoarthritis Therapeutics, 2019-2026
Figure 3: Global Market for Knee Osteoarthritis Therapeutics, by Region, 2019-2026
Figure 4: Global Market for Hip Osteoarthritis Therapeutics, 2019-2026
Figure 5: Global Market for Hip Osteoarthritis Therapeutics, by Region, 2019-2026
Figure 6: Global Market for Other Types of Osteoarthritis Therapeutics (Shoulder, Hand, Small Joint), 2019-2026
Figure 7: Global Market for Other Types of Osteoarthritis Therapeutics (Shoulder, Hand, Small Joint), by Region, 2019-2026
Figure 8: Global Market Shares of Osteoarthritis Therapeutics by Drug Type, 2020
Figure 9: Global Market for Viscosupplementation Agents as Osteoarthritis Therapeutics, 2019-2026
Figure 10: Global Market for Viscosupplementation Agents as Osteoarthritis Therapeutics, by Region, 2019-2026
Figure 11: Global Market for NSAIDs as Osteoarthritis Therapeutics, 2019-2026
Figure 12: Global Market for NSAIDs as Osteoarthritis Therapeutics, by Region, 2019-2026
Figure 13: Global Market Shares of NSAIDs as Osteoarthritis Therapeutics, by Drug Type, 2020
Figure 14: Global Market for Analgesics as Osteoarthritis Therapeutics, 2019-2026
Figure 15: Global Market for Analgesics as Osteoarthritis Therapeutics, by Region, 2019-2026
Figure 16: Global Market for Corticosteroids as Osteoarthritis Therapeutics, 2019-2026
Figure 17: Global Market for Corticosteroids as Osteoarthritis Therapeutics, by Region, 2019-2026
Figure 18: Global Market Shares of Osteoarthritis Therapeutics, by Route of Administration, 2020
Figure 19: Global Market for Osteoarthritis Therapeutics via the Parenteral Route, 2019-2026
Figure 20: Global Market for Osteoarthritis Therapeutics via the Parenteral Route, by Region, 2019-2026
Figure 21: Globa Market for Osteoarthritis Therapeutics via the Oral Route, 2019-2026
Figure 22: Global Market for Osteoarthritis Therapeutics via the Oral Route, by Region, 2019-2026
Figure 23: Global Market for Osteoarthritis Therapeutics via the Topical Route, 2019-2026
Figure 24: Global Market for Osteoarthritis Therapeutics via the Topical Route, by Region, 2019-2026
Figure 25: Global Market Shares of Osteoarthritis Therapeutics, by Drug Classification, 2020
Figure 26: Global Market for Prescription Osteoarthritis Therapeutics, 2019-2026
Figure 27: Global Market for Prescription Osteoarthritis Therapeutics, by Region, 2019-2026
Figure 28: Global Market for OTC Osteoarthritis Therapeutics, 2019-2026
Figure 29: Global Market for OTC Osteoarthritis Therapeutics, by Region, 2019-2026
Figure 30: Global Market for Osteoarthritis Therapeutics, by Region, 2019-2026
Figure 31: Global Market Shares of Osteoarthritis Therapeutics, by Region, 2020
Figure 32: North American Market Shares of Osteoarthritis Therapeutics, by Anatomy, 2020
Figure 33: North American Market Shares of Osteoarthritis Therapeutics, by Country, 2020
Figure 34: U.S. Market for Osteoarthritis Therapeutics, 2019-2026
Figure 35: Canadian Market for Osteoarthritis Therapeutics, 2020-2026
Figure 36: European Market Shares of Osteoarthritis Therapeutics, by Anatomy, 2020
Figure 37: European Market Shares of Osteoarthritis Therapeutics, by Country, 2020
Figure 38: German Market for Osteoarthritis Therapeutics, 2019-2026
Figure 39: French Market for Osteoarthritis Therapeutics, 2019-2026
Figure 40: U.K. Market for Osteoarthritis Therapeutics, 2019-2026
Figure 41: Italian Market for Osteoarthritis Therapeutics, 2019-2026
Figure 42: Spanish Market for Osteoarthritis Therapeutics, 2019-2026
Figure 43: Rest of European Market for Osteoarthritis Therapeutics, 2019-2026
Figure 44: Asia-Pacific Market Shares of Osteoarthritis Therapeutics, by Anatomy, 2020
Figure 45: Asia-Pacific Market Shares of Osteoarthritis Therapeutics, by Country, 2020
Figure 46: Chinese Market for Osteoarthritis Therapeutics, 2019-2026
Figure 47: Indian Market for Osteoarthritis Therapeutics, 2019-2026
Figure 48: Japanese Market for Osteoarthritis Therapeutics, 2019-2026
Figure 49: Australian Market for Osteoarthritis Therapeutics, 2019-2026
Figure 50: Rest of Asia-Pacific Market for Osteoarthritis Therapeutics, 2019-2026
Figure 51: Rest of the World Shares of Osteoarthritis Therapeutics, Market by Anatomy, 2020
Figure 52: Abbott Laboratories: Net Revenue, 2016-2020
Figure 53: Abbott Laboratories: Revenue Share, by Business Segment, 2020
Figure 54: Abbott Laboratories: Revenue Share, by Region, 2020
Figure 55: Anika Therapeutics Inc.: Net Revenue, 2016-2020
Figure 56: Anika Therapeutics Inc.: Revenue Share, by Business Segment, 2020
Figure 57: Anika Therapeutics Inc.: Revenue Share, by Region/Country, 2020
Figure 58: Bayer AG: Net Revenue, 2016-2020
Figure 59: Bayer AG: Revenue Share, by Business Segment, 2020
Figure 60: Bayer AG: Revenue Share, by Region, 2020
Figure 61: Bioventus: Net Revenue, 2018-2020
Figure 62: Bioventus: Revenue Share, by Business Segment, 2020
Figure 63: Bioventus: Revenue Share, by Region, 2020
Figure 64: Eli Lilly and Co.: Net Revenue, 2016-2020
Figure 65: Eli Lilly and Co.: Revenue Share, by Region, 2020
Figure 66: GlaxoSmithKline PLC: Net Revenue, 2016-2020
Figure 67: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2020
Figure 68: GlaxoSmithKline PLC: Revenue Share, by Region, 2021
Figure 69: Horizon Therapeutics PLC: Net Revenue, 2016-2020
Figure 70: Horizon Therapeutics PLC: Revenue Share, by Business Segment, 2020
Figure 71: Horizon Therapeutics PLC: Revenue Share, by Region, 2021
Figure 72: Horizon Therapeutics PLC: R&D Expenditure, 2016-2020
Figure 73: Johnson & Johnson Inc.: Net Revenue, 2016-2020
Figure 74: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2020
Figure 75: Johnson & Johnson Inc.: Revenue Share, by Region/Country, 2021
Figure 76: Novartis AG: Net Revenue, 2016-2020
Figure 77: Novartis AG: Revenue Share, by Business Segment, 2020
Figure 78: Novartis AG: Revenue Share, by Region/Country, 2021
Figure 79: Pfizer Inc.: Net Revenue, 2016-2020
Figure 80: Pfizer Inc.: Revenue Share, by Region/Country, 2021
Figure 81: Sanofi: Net Revenue, 2016-2020
Figure 82: Sanofi: Revenue Share, by Business Segment, 2020
Figure 83: Sanofi: Revenue Share, by Region/Country, 2021
Figure 84: Seikagaku Corp.: Net Revenue, 2016-2020
Figure 85: Seikagaku Corp.: Revenue Share, by Business Segment, 2020
Samples
LOADING...
Executive Summary
The growing geriatric population, rising incidence of OA, and growing demand for minimally invasive surgical procedures are driving the global osteoarthritis therapeutics market. Osteoarthritis is the most common type of arthritis, characterized by pain, swelling, and restricted joint motion. The knees, hips, and shoulders are the most common joints affected by osteoarthritis. Cartilage, a slippery tissue that covers up the ends of bones in a joint, gets damaged as a result of osteoarthritis. QA widely occurs in the elderly population and those who are obese.
Reasons for Doing This Study:
Osteoarthritis is a musculoskeletal disease resulting from the breakdown of joint cartilage and the underlying bone. It is a common musculoskeletal condition and a long-term, chronic disease. The common symptoms of osteoarthritis are joint pain and stiffness. Knee osteoarthritis is, in particular, a major cause of disability. As people age, bone cell production and the fluid present in knee joints both decrease, thereby increasing the friction between two joints. This condition results in bones rubbing together and creating stiffness, pain, and impaired movement. Osteoarthritis is associated with a wide range of modifiable and non-modifiable risk factors: obesity, lack of exercise, bone density, genetic predisposition, occupational injury, trauma and gender.
The different treatment types for osteoarthritis:
- Joint replacement surgery: An invasive replacement surgery that is costlier than viscosupplementation.
- Pharmacological treatment: Nonsteroidal anti-inflammatory drugs (NSAIDs), topical NSAIDs, symptomatic slow-acting drugs (SYSADOA), psychotropic drugs, opioid analgesics, COX-2inhibitors, and topical capsaicin for the treatment of osteoarthritis.
- Intra-articular treatment: Corticosteroids, hyaluronans and tidal irrigation medicines.
- Surgery: Arthroscopy, osteotomy and noncompartmental knee replacement surgeries.
- Non-pharmacological treatments: Acupuncture, herbal therapies, weight loss, orthodontic device treatment, and physical therapies.
- Viscosupplementation: A minimally invasive treatment for knee osteoarthritis. It involves the injection of hyaluronic acid into the knee joint to add viscous properties to the remaining synovial fluid. This procedure increases joint functioning and reduces pain. Intra-articular viscosupplementation with hyaluronic acid is gaining acceptance as a noninvasive procedure compared to knee replacement. Viscosupplementation is categorized into three product segments: single-injection cycle, three-injection cycle and five-injection cycle.
Companies Mentioned
- Abbott Laboratories
- Anika Therapeutics Inc.
- Bayer Ag
- Bioventus
- Eli Lilly And Co.
- Ferring B.V.
- Fidia Farmaceutici S.P.A.
- Flexion Therapeutics Inc.
- GlaxoSmithKline Plc
- Horizon Therapeutics Plc
- Johnson & Johnson Inc.
- Novartis Ag
- Pfizer Inc.
- Sanofi
- Seikagaku Corp.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 133 |
| Published | January 2022 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 7.4 Billion |
| Forecasted Market Value ( USD | $ 11.2 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
